手机购彩

Hengrui Medicine Approves Another Innovative Drug SHR5126
Recently, Hengrui Medicine received the "Clinical Trial Notification" approved and issued by the State Drug Administration, and approved the company's innovative drug SHR5126 to carry out clinical trials, which are intended to be used to treat patients with solid tumors. Tumors are clinically divided into solid tumors and non-solid tumors. Solid tumors are tangible tumors. They are tangible masses that can be reached through clinical examinations such as X-rays, CT scans, B-ultrasounds, or palpation. The incidence is much higher than non-solid ...
2020-02-25
Hengrui Medicine donates another 3 million yuan worth of innovative medicine to aid Hubei
At present, the epidemic of new crown pneumonia in many places such as Wuhan, Hubei, the severe prevention and control situation, and shortage of medical resources have aroused great concern from the society. Under the epidemic, the normal medical needs of special populations such as cancer patients also need to be protected urgently. Recently, Hengrui Medicine launched the "Escort for Hubei Cancer Patients" charity project, which will donate an innovative drug sulfur with a market value of more than 3 million yuan to cancer patients in Hubei Province who need treatment ...
2020-02-18
Hengrui Pharmaceutical's innovative drug SHR0302 tablets approved for clinical use
Recently, Ruishi Biopharmaceutical Co., Ltd., a subsidiary of Hengrui Medicine, received the "Clinical Trial Notification" approved by the State Drug Administration, and approved the company's innovative drug SHR0302 to carry out clinical trials intended for alopecia areata. Alopecia areata is a type of non-scarring alopecia, which often occurs in the hairy parts of the body. The local skin is normal and there are no conscious symptoms. It is the second highest incidence of hair loss worldwide. At home and abroad ...
2020-02-17
Xiangyun Long, Secretary of the Lianyungang Municipal Party Committee, and his party investigated the production of Hengrui Pharmaceutical's anti-epidemic drugs
On the morning of January 30, Xiangyun Long, secretary of the Lianyungang Municipal Party Committee and director of the Standing Committee of the Municipal People's Congress, went to Hengrui Pharmaceutical to investigate the company's production of anti-epidemic drugs and measures to prevent new coronavirus among employees. City leaders Liu Haitao, Yin Zheqiang, and Huang Yuanzheng participated in the investigation. Jiang Sumei, deputy general manager of Hengrui Medicine, and others received the survey. Secretary Xiang and his entourage made a detailed understanding of the company's anti-epidemic drugs in Hengrui Pharmaceutical New Pharmaceutical Industrial Park ...
2020-01-30
Helping Wuhan | Hengrui Pharmaceutical donates RMB 5 million in special donations and medical protection materials
Recently, pneumonia epidemics of new coronavirus infection occurred in Wuhan and other places in Hubei Province. The situation of prevention and control is severe, and medical protection equipment is urgent. It has drawn great attention from all walks of life and affected the hearts of all the employees of Hengrui Medicine. On the occasion of the Lunar New Year, Hengrui Medicine donated a total of 5 million yuan to Wuhan Charity Federation (the designated recipient unit of Wuhan New Crown Pneumonia Prevention and Control Headquarters) and some medical institutions ...
2020-01-25
上一页 1 2 3 4 ... 12 下一页 Total 96 recordsPrevious page 1 2 3 4 ... 12Next page